Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Gross margin | — | — |
| R&D | $50.4K | $48.3K |
| Operating income | −$10.7M | −$5.9M |
| EBITDA | −$10.7M | −$5.9M |
| Net income | −$10.2M | −$14.1M |
| Net margin | — | — |
| EPS (diluted) | -0.18 | -0.15 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds MCURF.
No tracked institution reports a position in MCURF as of their last filing.
No one on the platform has traded MCURF yet.
| $108M |
| — |
| ETXPFE-therapeutics Plc | $0.13 | +0.00% | $76M | — |
| HRPMFHerantis Pharma Oyj | $3.51 | +0.00% | $59M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.